RYTM
Neutral signalScored 2026-09-17 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Rhythm Pharmaceuticals, Inc.
- Nom
- Rhythm Pharmaceuticals, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $6.2B
- Employés
- 414
- PDG
- David Meeker
- Site web
- https://www.rhythmtx.com
- Marché
- BIOABLTEBMEABMRNGPCRMAZE
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 50 000 titres (~5 087 320,00 $ US)
- Insiders
- Meeker David P
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$14,875,100
Avg sell (VWAP, 90d window) $114.85 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$14,875,100 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-14
- Last synced
-
2026-09-20 09:54:07
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-14 | Meeker David P | Sell · S S · 10b5-1 | 2,300 | $105.19 | ≈ $241,937 | Form 4 |
| 2026-08-31 | Smith Hunter C | Sell · S S · 10b5-1 | 28,188 | $106.20 | ≈ $2,993,647 | Form 4 |
| 2026-08-13 | Garfield Alastair | Sell · S S · 10b5-1 | 800 | $119.17 | ≈ $95,335 | Form 4 |
| 2026-08-13 | Shulman Joseph | Sell · S S · 10b5-1 | 5,079 | $119.75 | ≈ $608,210 | Form 4 |
| 2026-08-13 | Lee Jennifer Kayden | Sell · S S · 10b5-1 | 75,834 | $117.38 | ≈ $8,901,531 | Form 4 |
| 2026-08-12 | Mazabraud Yann | Sell · S S · 10b5-1 | 17,319 | $117.47 | ≈ $2,034,439 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-09-17 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $14.9M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $14.9M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 4.41 · operating margin -101% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 89.7% | 89.7% | 88.0% | 91.0% | 81.0% | |
| Ebit Margin | -92.5% | -184.2% | -219.8% | -744.2% | -2207.1% | |
| Ebitda Margin | -91.8% | -183.0% | -217.6% | -737.1% | -2170.4% | |
| Operating Profit Margin | -101.2% | -204.0% | -238.1% | -757.9% | -5391.9% | |
| Pretax Profit Margin | -103.3% | -200.0% | -237.8% | -766.2% | -2207.1% | |
| Continuous Operations Profit Margin | -103.6% | -200.3% | -238.5% | -766.2% | -2207.1% | |
| Net Profit Margin | -103.6% | -200.3% | -238.5% | -766.2% | -2207.1% | |
| Bottom Line Profit Margin | -106.4% | -203.3% | -238.5% | -766.2% | -2207.1% | |
| Current Ratio | 4.407 | 3.239 | 5.584 | 8.898 | 7.101 | |
| Quick Ratio | 4.164 | 3.077 | 5.428 | 8.825 | 7.099 | |
| Solvency Ratio | -0.929 | -1.138 | -1.122 | -1.518 | -1.509 | |
| Cash Ratio | 0.513 | 0.772 | 1.088 | 3.207 | 1.364 | |
| Price To Earnings Ratio | -34.418 | -12.899 | -14.366 | -8.296 | -7.285 | |
| Price To Earnings Growth Ratio | 1.214 | -0.362 | 1.627 | -0.053 | 0.136 | |
| Forward Price To Earnings Growth Ratio | 1.214 | -0.362 | 1.627 | -0.053 | 0.136 | |
| Price To Earnings Diluted Ratio | -34.418 | -12.899 | -14.366 | -8.296 | -7.285 | |
| Price To Earnings Diluted Growth Ratio | 1.214 | -0.362 | 1.627 | -0.053 | 0.136 | |
| Price To Book Ratio | 25.760 | 20.751 | 15.618 | 5.743 | 1.742 | |
| Price To Sales Ratio | 36.657 | 26.240 | 34.241 | 64.208 | 156.947 | |
| Price To Free Cash Flow Ratio | -59.642 | -29.984 | -19.465 | -8.541 | -3.269 | |
| Price To Operating Cash Flow Ratio | -60.133 | -29.984 | -19.472 | -8.751 | -3.390 | |
| Debt To Assets Ratio | 0.008 | 0.010 | 0.004 | 0.005 | 0.008 | |
| Debt To Equity Ratio | 0.015 | 0.024 | 0.007 | 0.007 | 0.009 | |
| Debt To Capital Ratio | 0.015 | 0.023 | 0.007 | 0.007 | 0.009 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.778 | 2.384 | 1.960 | 1.447 | 1.160 | |
| Working Capital Turnover Ratio | 0.612 | 0.509 | 0.273 | 0.082 | 0.015 | |
| Operating Cash Flow Ratio | -1.092 | -0.986 | -2.466 | -4.357 | -3.362 | |
| Operating Cash Flow Sales Ratio | -0.610 | -0.875 | -1.758 | -7.337 | -46.291 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.008 | 1.000 | 1.000 | 1.025 | 1.037 | |
| Debt Service Coverage Ratio | -8.484 | -11.573 | -12.167 | -33.502 | 0.000 | |
| Interest Coverage Ratio | -9.329 | -12.887 | -13.271 | -34.447 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -28.977 | -28.918 | -108.061 | -89.212 | -57.234 | |
| Capital Expenditure Coverage Ratio | -121.380 | 0.000 | -2,896.957 | -40.511 | -26.868 | |
| Dividend Paid And Capex Coverage Ratio | -121.380 | -28.685 | -2,896.957 | -40.511 | -26.868 | |
| Dividend Payout Ratio | 0.000 | -0.015 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -39.660 | -13.983 | -15.389 | -7.989 | -6.403 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 89.7% | 0.0% | ▲1.8% |
| Ebit Margin | -92.5% | ▲91.7% | ▲597.1% |
| Ebitda Margin | -91.8% | ▲91.2% | ▲588.2% |
| Operating Profit Margin | -101.2% | ▲102.8% | ▲1237.4% |
| Pretax Profit Margin | -103.3% | ▲96.7% | ▲599.6% |
| Continuous Operations Profit Margin | -103.6% | ▲96.7% | ▲599.6% |
| Net Profit Margin | -103.6% | ▲96.7% | ▲599.6% |
| Bottom Line Profit Margin | -106.4% | ▲96.9% | ▲597.9% |
| Current Ratio | 4.407 | ▲1.168 | ▼-1.439 |
| Quick Ratio | 4.164 | ▲1.087 | ▼-1.554 |
| Solvency Ratio | -0.929 | ▲0.209 | ▲0.314 |
| Cash Ratio | 0.513 | ▼-0.259 | ▼-0.876 |
| Price To Earnings Ratio | -34.418 | ▼-21.519 | ▼-18.965 |
| Price To Earnings Growth Ratio | 1.214 | ▲1.577 | ▲0.702 |
| Forward Price To Earnings Growth Ratio | 1.214 | ▲1.577 | ▲0.702 |
| Price To Earnings Diluted Ratio | -34.418 | ▼-21.519 | ▼-18.965 |
| Price To Earnings Diluted Growth Ratio | 1.214 | ▲1.577 | ▲0.702 |
| Price To Book Ratio | 25.760 | ▲5.010 | ▲11.837 |
| Price To Sales Ratio | 36.657 | ▲10.417 | ▼-27.002 |
| Price To Free Cash Flow Ratio | -59.642 | ▼-29.658 | ▼-35.462 |
| Price To Operating Cash Flow Ratio | -60.133 | ▼-30.150 | ▼-35.787 |
| Debt To Assets Ratio | 0.008 | ▼-0.002 | ▲0.001 |
| Debt To Equity Ratio | 0.015 | ▼-0.009 | ▲0.002 |
| Debt To Capital Ratio | 0.015 | ▼-0.009 | ▲0.002 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.778 | ▼-0.606 | ▲0.033 |
| Working Capital Turnover Ratio | 0.613 | ▲0.104 | ▲0.314 |
| Operating Cash Flow Ratio | -1.092 | ▼-0.106 | ▲1.361 |
| Operating Cash Flow Sales Ratio | -0.610 | ▲0.266 | ▲10.765 |
| Free Cash Flow Operating Cash Flow Ratio | 1.008 | ▲0.008 | ▼-0.006 |
| Debt Service Coverage Ratio | -8.484 | ▲3.089 | ▲4.662 |
| Interest Coverage Ratio | -9.329 | ▲3.558 | ▲4.658 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -28.977 | ▼-0.059 | ▲33.504 |
| Capital Expenditure Coverage Ratio | -121.380 | ▼-121.380 | ▲495.764 |
| Dividend Paid And Capex Coverage Ratio | -121.380 | ▼-92.695 | ▲501.500 |
| Dividend Payout Ratio | 0.000 | ▲0.015 | ▲0.003 |
| Enterprise Value Multiple | -39.660 | ▼-25.677 | ▼-22.975 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $6.96B | $3.41B | $2.65B | $1.52B | $495.0M | |
| Enterprise value | $6.91B | $3.33B | $2.59B | $1.39B | $438.3M | |
| EV / Sales | 36.39x | 25.59x | 33.48x | 58.89x | 138.97x | |
| EV / Op. cash flow | -59.70x | -29.23x | -19.04x | -8.03x | -3.00x | |
| EV / Free cash flow | -59.21x | -29.23x | -19.03x | -7.83x | -2.89x | |
| EV / EBITDA | -39.66x | -13.98x | -15.39x | -7.99x | -6.40x | |
| Net debt / EBITDA | 0.29x | 0.36x | 0.35x | 0.72x | 0.83x | |
| Current ratio | 4.41x | 3.24x | 5.58x | 8.90x | 7.10x | |
| Income quality | 0.59x | 0.44x | 0.74x | 0.96x | 2.10x | |
| Graham net-net | $3 | $2 | $2 | $4 | $5 | |
| Tax burden | 100.3% | 100.1% | 100.3% | 100.0% | 100.0% | |
| Interest burden | 111.7% | 108.6% | 108.2% | 103.0% | 100.0% | |
| Working capital | $361.0M | $258.7M | $253.1M | $314.4M | $265.0M | |
| Invested capital | $370.4M | $269.0M | $262.2M | $325.7M | $274.0M | |
| Return on assets | -40.9% | -66.4% | -55.5% | -47.4% | -21.1% | |
| Operating ROA | -44.0% | -73.2% | -51.6% | -50.3% | -65.8% | |
| Return on tangible assets | -41.4% | -67.5% | -56.7% | -48.4% | -21.4% | |
| Return on equity | -72.8% | -158.4% | -108.8% | -68.5% | -24.5% | |
| Return on invested capital | -51.2% | -95.9% | -66.2% | -52.2% | -59.3% | |
| Return on capital employed | -51.3% | -95.9% | -66.4% | -52.3% | -59.4% | |
| Earnings yield | -2.8% | -7.6% | -7.0% | -11.9% | -14.1% | |
| Free cash flow yield | -1.7% | -3.3% | -5.1% | -11.7% | -30.6% | |
| Capex / Op. cash flow | -0.8% | 0.0% | -0.0% | -2.5% | -3.7% | |
| Capex / Depreciation | 71.2% | 0.0% | 2.7% | 256.0% | 469.3% | |
| Capex / Sales | 0.5% | 0.0% | 0.1% | 18.1% | 172.3% | |
| SG&A / Sales | 102.7% | 110.9% | 151.8% | 389.3% | 2171.4% | |
| R&D / Sales | 88.2% | 182.9% | 174.3% | 459.6% | 3301.5% | |
| Stock comp / Sales | 35.2% | 30.5% | 42.0% | 83.9% | 659.6% | |
| Intangibles / Total assets | 1.1% | 1.6% | 2.1% | 2.1% | 1.4% | |
| Days sales outstanding | 50d | 52d | 70d | 96d | 119d | |
| Days payables outstanding | 261d | 337d | 192d | 821d | 3496d | |
| Operating cycle | 532d | 564d | 408d | 595d | 186d | |
| Cash conversion cycle | 271d | 227d | 217d | -226d | -3310d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-16 David Meeker Sells 50,000 Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM - Get Free Report) CEO David Meeker sold 50,000 shares of the company''s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $102.67, for a total transaction of $5,133,500.00. Following the transaction, the chief executive officer owned 239,258 shares in the
- 2026-09-16 Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 5.3% on Insider Selling Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM - Get Free Report) traded down 5.3% during mid-day trading on Tuesday after an insider sold shares in the company. The company traded as low as $97.67 and last traded at $97.0350. Approximately 54,752 shares traded hands during trading, a decline of 93% from the average session volume of 750,485 shares.
- 2026-09-15 Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-10 Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting -- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France – -- Phase 3 analyses demonstrated improvements across multiple cardiometabolic risk indices with setmelanotide in acquired HO -- BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced Rhythm and its collaborators will present three posters and three oral presentations relating to the company''s work in rare melanocortin-4 receptor (MC4R) pathway diseases at the 64th Annual European Society for Paediatric Endocrinology (ESPE) Meeting taking place September 8-10 in Marseille, France.
- 2026-08-28 Here Are Friday’s Top Wall Street Analyst Research Calls: Baozun, Commerce Bancshares, Element Solutions, Evolution Petroleum, Petrobras, Rythm Pharmaceuticals, Terawulf, UMB Financial, Workday, and More NVIDIA''s blockbuster earnings sent shockwaves through tech on Thursday, but Wall Street analysts were busy reshaping the landscape elsewhere, issuing a flurry of upgrades, downgrades, and fresh initiations across energy, crypto infrastructure, banking, and biotech.
- 2026-08-28 Bank of New York Mellon Corp Purchases Shares of 394,044 Rhythm Pharmaceuticals, Inc. $RYTM Bank of New York Mellon Corp acquired a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 394,044 shares of the company''s stock, valued at approximately $43,751,000. Bank of New York Mellon Corp owned
- 2026-08-26 Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here''s What His New Positions Reveal Duquesne Family Office has beefed up its healthcare holdings.
- 2026-08-24 Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan -- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --
- 2026-08-23 Eli Lilly and Novo Nordisk Can''t Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can Rhythm Pharmaceuticals develops medicines for rare forms of obesity. The company has little competition in its target market.
- 2026-08-18 Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise Rhythm Pharmaceuticals is transitioning from a single rare disease drug to a broad MC4R therapeutic franchise, leveraging multiple formulations for market segmentation. IMCIVREE''s AHO approval and over 400 patient start forms signal robust demand, with a scalable commercial model targeting endocrinologists and neuro-oncologists. RYTM''s pipeline—daily, weekly, and oral MC4R agonists—aims to preempt competition and expand reach, while strong gross margins offer operating leverage.